Extensive single-cell RNA sequencing showed that PDOs preserve the subclonal heterogeneity of BoM epithelial cells and show gene expression highly related to BoM, suggesting the use of breast cancer organoids to explore tumor heterogeneity and evolution, as well as precision medicine treatments (92). This evidence concerns the gene GRHL2 and breast carcinoma.